1Sokoloff, B, Redd, JB & Dutcher, R (1950) Capillary fragility and vitamin ‘P’ protective action against radiation. Proc Soc Exp Biol Med 75, 6–9.
2Clark, WG & MacKay, EM (1950) Effect of flavonoid (vitamin P-like) substances on histamine toxicity, anaphylactic shock, histamine-enhanced capillary permeability to dye, and bleeding time; with data on the toxicity of flavonoids. J Allergy 21, 133–147.
3Salgado, E & Green, DM (1956) Action of bioflavanoids on inflammation. J Appl Physiol 6, 647–650.
4Agullo, G, Gamet-Payrastre, L, Manenti, S, Viala, C, Remesy, C, Chap, H & Payrastre, B (1997) Relationship between flavonoid structure and inhibition of phosphatidylinositol 3-kinase: a comparison with tyrosine kinase and protein kinase C inhibition. Biochem Pharmacol 53, 1649–1657.
5Virgili, F, Acconia, F, Ambra, R, Rinna, A, Totta, P & Marino, M (2004) Nutritional flavanoids modulate estrogen receptor α signalling. IUBMB Life 56, 145–151.
6Totta, P, Acconcia, F, Leone, S, Cardillo, I & Marino, M (2004) Mechanisms of naringenin-induced apoptotic cascade in cancer cells: involvement of estrogen receptor α and β signalling. IUBMB Life 56, 491–499.
7Shen, SC, Ko, CH, Tseng, SW, Tsai, SH & Chen, YC (2004) Structurally related antitumor effects of flavanones in vitro and in vivo: involvement of caspase 3 activation, p21 gene expression, and reactive oxygen species production. Toxicol Appl Pharmacol 197, 84–95.
8Pollard, SE, Whiteman, M & Spencer, JP (2006) Modulation of peroxynitrite-induced fibroblast injury by hesperetin: a role for intracellular scavenging and modulation of ERK signalling. Biochem Biophys Res Commun 347, 916–923.
9Middelton, E (1998) . In Flavonoids in the Living System, chapter 13, pp. 175–182 [JA, Manthey and Vuslig, BS, editors]. New York: Plenum Press.
10Ko, CH, Shen, SC, Lin, HY, Hou, WC, Lee, WR, Yang, LL & Chen, YC (2002) Flavanones structure-related inhibition on TPA-induced tumor promotion through suppression of extracellular signal-regulated protein kinases: involvement of prostaglandin E2 in anti-promotive process. J Cell Physiol 193, 93–102.
11Orallo, F, Camina, M, Alvarez, E, Basaran, H & Lugnier, C (2005) Implication of cyclic nucleotide phosphodiesterase inhibition in the vasorelaxant activity of the citrus-fruits flavonoid (+/ − )-naringenin. Planta Med 71, 99–107.
12Manthay, JA, Grohmann, K & Guthrie, N (2001) Biological properties of citrus flavanoids pertaining to cancer and inflammation. Curr Med Chem 8, 135–153.
13Santos, KF, Oliveira, TT, Nagem, TJ, Pinto, AS & Oliveira, MG (1999) Hypolipidaemic effects of naringenin, rutin, nicotinic acid and their associations. Pharmacol Res 40, 493–496.
14Crespo, ME, Galvez, J, Cruz, T, Ocete, MA & Zarzuelo, A (1999) Anti-inflammatory activity of diosmin and hesperidin in rat colitis induced by TNBS. Planta Med 65, 651–653.
15So, FV, Guthrie, N, Chambers, AF, Moussa, M & Carroll, KK (1996) Inhibition of human breast cancer cell proliferation and delay of mammary tumourigenesis by flavonoids and citrus juices. Nutr Cancer 262, 167–181.
16Tanaka, T, Makita, H, Kawabata, K, Mori, H, Kakumoto, M, Satoh, K, Hara, A, Sumida, T, Tanaka, T & Ogawa, H (1997) Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis 18, 957–965.
17Guthrie, N & Carroll, KK (1998) Inhibition of mammary cancer by citrus flavonoids. Adv Exp Med Biol 439, 227–236.
18Kim, JY, Jung, KJ, Choi, JS & Chung, HY (2006) Modulation of the age-related nuclear factor-κB (NF-κB) pathway by hesperetin. Aging Cell 5, 401–411.
19Knekt, P, Kumpulainen, J, Jarvinen, R, Rissanen, H, Heliovaara, M, Reunanen, A, Hakulinen, T & Aromaa, A (2002) Flavonoid intake and risk of chronic diseases. Am J Clin Nutr 76, 560–568.
20Lagiou, P, Samoli, E, Lagiou, A, Peterson, J, Tzonou, A, Dwyer, J & Trichopoulos, D (2004) Flavonoids, vitamin C and adenocarcinoma of the stomach. Cancer Causes Control 15, 67–72.
21Chan, JM, Wang, F & Holly, EA (2005) Vegetable and fruit intake and pancreatic cancer in a population-based case–control study in the San Francisco Bay area. Cancer Epidemiol Biomarkers Prev 14, 2093–2097.
22Maserejian, NN, Giovannucci, E, Rosner, B, Zavras, A & Joshipura, K (2006) Prospective study of fruits and vegetables and risk of oral premalignant lesions in men. Am J Epidemiol 164, 556–566.
23Hertog, MG, Hollman, PC, Katan, MB & Kromhout, D (1993) Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr Cancer 20, 21–29.
24Kumpulainen, JT (2001) . In Proceedings of the Third International Conference on Natural Antioxidants and Anticarcinogens in Food, Health, and Disease, p. 24 [Voutilainen, S and Salonen, JT, editors]. Kuopio, Finland: Kuopio University Publications D. Medical Sciences.
25Manach, C, Williamson, G, Morand, C, Scalbert, A & Remesy, C (2005) Bioavailabilty and bioefficacy of polyphenols in humans. 1. Review of 97 bioavailability studies. Am J Clin Nutr 81, Suppl. 1, 230S–242S.
26Erlund, I, Meririnne, E, Alfthan, G & Aro, A (2001) Plasma kinetics and urinary excretion of the flavanones naringenin and hesperetin in humans after ingestion of orange juice and grapefruit juice. J Nutr 131, 235–241.
27Manach, C, Morand, C, Gil-Izquierdo, A, Bouteloup-Demange, C & Remesy, C (2003) Bioavailability in humans of the flavanones hesperidin and narirutin after the ingestion of two doses of orange juice. Eur J Clin Nutr 57, 235–242.
28Kroon, PA, Clifford, MN, Crozier, A, Day, AJ, Donovan, JL, Manach, C & Williamson, G (2004) How should we assess the effects of exposure to dietary polyphenols in vitro? Am J Clin Nutr 80, 15–21.
29Davis, BD, Needs, PW, Kroon, PA & Brodbelt, JS (2006) Identification of isomeric flavonoid glucuronides in urine and plasma by metal complexation and LC-ESI-MS/MS. J Mass Spectrom 41, 911–920.
30Davis, BD & Brodbelt, JS (2005) LC-MSn methods for saccharide characterization of monoglycosyl flavonoids using postcolumn manganese complexation. Anal Chem 77, 1883–1890.
31Wojcińska, M, Williams, J, Mabry, TJ, Ahmed, AA, Davis, BD, Tóth, G, El-Sayed, NH, Matławska, I & Clevinger, J (2006) Flavonol triglycosides from the leaves of Silphium albiflorum. Nat Prod Comm 1, 941–948.
32Borradaile, NM, Carroll, KK & Kurowska, EM (1999) Regulation of HepG2 cell apolipoprotein B metabolism by the citrus flavanones hesperetin and naringenin. Lipids 34, 591–598.
33Doostdar, H, Burke, MD & Mayer, RT (2000) Bioflavonoids: selective substrates and inhibitors for cytochrome P450 CYP1A and CYP1B1. Toxicology 144, 31–38.
34Jeong, YJ, Choi, YJ, Kwon, HM, Kang, SW, Park, HS, Lee, M & Kang, YH (2005) Differential inhibition of oxidized LDL-induced apoptosis in human endothelial cells treated with different flavonoids. Br J Nutr 93, 581–591.
35Dew, TP, Day, AJ & Morgan, MR (2005) Xanthine oxidase activity in vitro: effects of food extracts and components. J Agric Food Chem 53, 6510–6515.
36Hirata, A, Murakami, Y, Shoji, M, Kadoma, Y & Fujisawa, S (2005) Kinetics of radical-scavenging activity of hesperetin and hesperidin and their inhibitory activity on COX-2 expression. Anticancer Res 25, 3367–3374.
37Choi, EJ, Kim, GD, Chee, KM & Kim, GH (2006) Effects of hesperetin on vessel structure formation in mouse embryonic stem (mES) cells. Nutrition 22, 947–951.
38Jin, YR, Han, XH, Zhang, YH, Lee, JJ, Lim, Y, Chung, JH & Yun, YP (2007) Antiplatelet activity of hesperetin, a bioflavonoid, is mainly mediated by inhibition of PLC-γ2 phosphorylation and cyclooxygenase-1 activity. Atherosclerosis 194, 144–152.
39Felgines, C, Texier, O, Morand, C, Manach, C, Scalbert, A, Regerat, F & Remesy, C (2000) Bioavailability of the flavanone naringenin and its glycosides in rats. Am J Physiol Gastrointest Liver Physiol 279, G1148–G1154.
40Silberberg, M, Morand, C, Mathevon, T, Besson, C, Manach, C, Scalbert, A & Remesy, C (2006) The bioavailability of polyphenols is highly governed by the capacity of the intestine and of the liver to secrete conjugated metabolites. Eur J Nutr 45, 88–96.
41Nielsen, IL, Chee, WS, Poulsen, L, Offord-Cavin, E, Rasmussen, SE, Frederiksen, H, Enslen, M, Barron, D, Horcajada, MN & Williamson, G (2006) Bioavailability is improved by enzymatic modification of the citrus flavonoid hesperidin in humans: a randomized, double-blind, crossover trial. J Nutr 136, 404–408.
42Hollman, PC, Bijsman, MN, van Gameren, Y, Cnossen, EP, de Vries, JH & Katan, MB (1999) The sugar moiety is a major determinant of the absorption of dietary flavonoid glycosides in man. Free Radic Res 31, 569–573.
43Felgines, C, Talavera, S, Gonthier, MP, Texier, O, Scalbert, A, Lamaison, JL & Remesy, C (2003) Strawberry anthocyanins are recovered in urine as glucuro- and sulfoconjugates in humans. J Nutr 133, 1296–1301.
44Hollands, W, Brett, GM, Dainty, JR, Teucher, B & Kroon, PA (2008) Urinary excretion of strawberry anthocyanins is dose-dependent for physiological oral doses of fresh fruit. Molec Nutr Food Res .
45Nemeth, K, Plumb, GW, Berrin, JG, Juge, N, Jacob, R, Naim, HY, Williamson, G, Swallow, DM & Kroon, PA (2003) Deglycosylation by small intestinal epithelial cell β-glucosidases is a critical step in the absorption and metabolism of dietary flavanoid glycosides in humans. Eur J Nutr 42, 29–42.
46Berrin, JG, Czjzek, M, Kroon, PA, McLauchlan, WR, Puigserver, A, Williamson, G & Juge, N (2003) Substrate (aglycone) specificity of human cytosolic β-glucosidase. Biochem J 373, 41–48.
47Kanaze, FI, Bounartzi, MI, Georgarakis, M & Niopas, I (2007) Pharmacokinetics of the citrus flavanone aglycones hesperetin and naringenin after single oral administration in human subjects. Eur J Clin Nutr 61, 472–477.
48Berrin, JG, McLauchlan, WR, Needs, P, Williamson, G, Puigserver, A, Kroon, PA & Juge, N (2002) Functional expression of human liver cytosolic β-glucosidase in Pichia pastoris. Insights into its role in the metabolism of dietary glucosides. Eur J Biochem 269, 249–258.
49Day, AJ, Gee, JM, DuPont, MS, Johnson, IT & Williamson, G (2003) Absorption of quercetin-3-glucoside and quercetin-4′-glucoside in the rat small intestine: the role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. Biochem Pharmacol 65, 1199–1206.
50O'Leary, KA, Day, AJ, Needs, PW, Mellon, FA, O'Brien, NM & Williamson, G (2003) Metabolism of quercetin-7- and quercetin-3-glucuronides by an in vitro hepatic model: the role of human β-glucuronidase, sulfotransferase, catechol-O-methyltransferase and multi-resistant protein 2 (MRP2) in flavonoid metabolism. Biochem Pharmacol 65, 479–491.
51Sesink, AL, Arts, IC, de Boer, VC, Breedveld, P, Schellens, JH, Hollman, PC & Russel, FG (2005) Breast cancer resistance protein (Bcrp1/Abcg2) limits net intestinal uptake of quercetin in rats by facilitating apical efflux of glucuronides. Mol Pharmacol 67, 1999–2006.
52Boersma, MG, van der Woude, H, Bogaards, J, Boeren, S, Vervoort, J, Cnubben, NH, van Iersel, ML, van Bladeren, PJ & Rietjens, IM (2002) Regioselectivity of phase II metabolism of luteolin and quercetin by UDP-glucuronosyl transferases. Chem Res Toxicol 15, 662–670.
53Ameer, B, Weintraub, RA, Johnson, JV, Yost, RA & Rouseff, RL (1996) Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharmacol Ther 60, 34–40.